Executive interview – TxCell

Executive interview – TxCell

TxCell offers a rare investment opportunity as it is the only company applying CAR-T technology to regulatory T-cells (Tregs) for autoimmune and inflammatory therapy. Tregs have very powerful control functions in the immune system. The first CAR-Treg studies are planned in transplantation starting in 2018, followed by possible trials in other indications like multiple sclerosis.


You may also be interested in these:

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free